Navigation Links
cAMP DataFile: Homogenous Cyclic AMP detection using High Efficiency Fluorescence Polarization

A Sensitive, Robust, Homogenous, and Rapid Assay
Uses High Efficiency Fluorescence Polarization (HEFP) detection method
Detects pmol amounts of cAMP
Optimized for cell extract and enzyme preparations
Requires no separation or wash steps
Available in a kit and in bulk packaging


Introduction
Cyclic adenosine monophosphate (cAMP) is a second messenger involved in the transduction of extracellular signals. The signal is initiated by the binding of a ligand to a G-protein coupled receptor followed by a series of enzyme mediated steps leading to the activation of the enzyme adenylyl cyclase. Adenylyl cyclase converts ATP into cyclic AMP that in turn activates protein kinases. Protein kinase activity is correlated to the intracellular concentration of cyclic AMP. The level of cyclic AMP is reduced by phosphodiesterase. Assays that determine the activities of these cellular regulators are important tools for high-throughput screening laboratories.


Intended Use
The cAMP Assay Kit is designed to determine concentrations of cyclic AMP in solution. The sources of cyclic AMP analyte may either be in vitro enzyme preparations or cell extracts.


Principle of the Assay
The assay is an antibody-mediated competitive binding reaction with a High Efficiency Fluorescence Polarization (HEFP) read out. Cyclic AMP (analyte) from sample, calibrators, or controls competes with fluorescein-labeled cAMP (tracer) for a limited number of anti-cAMP antibodies. In the absence of analyte, a maximal amount of tracer will be bound to the antibody.

Addition of analyte competes with the tracer for the limited binding sites, so that the extent of polarization is inversely proportional to the concentration of analyte.

HEFP is a detection method that discriminates on th e basis of molecular size. The tracer-antibody complex rotates more slowly than free tracer so that the fluorescence appears polarized. Displacement of the tracer by the analyte from the antibody results in a decrease in polarization. Free tracer is small, spins rapidly relative to the fluorescence lifetime and thus emits light that is detected as having low polarization. HEFP does not require physical separation steps or wash steps.

The reagents have been optimized to provide a sensitive, robust and rapid homogeneous assay. Individual assays of cell lysates or of purified adenylyl cyclase will require optimization and validation based upon the requirements of the individual test systems.


Kit Contents
The kit contains anti-cAMP antibody (100X), tracer (fluorescein-labeled cAMP, 100X), calibrator cAMP (500 M) and HEFP Assay Buffer. When used as suggested, each kit provides sufficient reagents for 800 40-L assays.


Assay Conditions
Samples or calibrators containing cAMP are mixed with fluorescein-labeled tracer and anti-cAMP antibody in microplate wells and analyzed after 2 hours.

The kit is designed for standard 384-well microplates with a 40 L sample volume. It can be scaled down to an 8 L sample volume, with the same performance, using HE microplates in any instrument in the Criterion family.


Applications
Measurement of adenylyl cyclase activity1
Monitoring phosphodiesterase activity2


Assay Performance
Calibration curve: A calibration curve was performed in 384-well microplates with a final volume of 40 L. Background signals (buffer only or antibody only) were appropriately subtracted and net polarization calculated. The minimum detectable concentration was 0.1 pmol.


Measuring adenylyl cyclase activity: Cultured T-47D cells were treated for 15 min with either buffer (control), forskolin, isoproternol, or isoproterenol and propranolol. Formation of cAMP was determined with the cAMP Assay Kit. The assay was performed in 384-well microplates in a final volume of 40 L. Each treatment group was performed in triplicate.



Please contact your local Molecular Devices representative for price and delivery information.


Certain aspects of the technology and design of Molecular Devices products are protected under current or pending patents.


1 Chedeville, A. et al. FEBS Letters 319:171176 1993
2 Chan, S.C. and Hanifan, J.M. S. J. Clin. Med. 121:4451 1993


back to top


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. TKXtra DataFile: Homogenous tyrosine kinase detection using High Efficiency Fluorescence Polarization
2. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
3. Monitoring transfection efficiency by green fluorescent protein (GFP) detection with the Agilent 2100 bioanalyzer
4. Apoptosis detection by annexin V and active caspase-3 with the Agilent 2100 bioanalyzer
5. Sensitive detection of tumor cells in peripheral blood of carcinoma patients by a reverse transcription PCR method
6. Rapid detection of genomic duplications and deletions using the Agilent 2100 bioanalyzer
7. Mutation detection for the K- rasand P16 genes
8. Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager
9. The combination of monolithic columns and modern HPLC/MS/MS instrumentation for high chromatographic throughput and sensitive detection of beta-agonists
10. Front-face detection for high-concentrate, opaque or solid sample
11. Outstanding transfection rates using the Multiporator
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... , February 11, 2016 Non-profit ... Promote Genetic Understanding to Support Research and Discovery ... 100K, today announced an ambitious plan to sequence 100,000 individuals. ... Asian countries and at least 7 of North and East ... In the first phase, the project will focus on creating ...
(Date:2/11/2016)... Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results ... --> --> For the fourth quarter ... or $0.34 loss per share, compared to a net loss of ... in 2014. For the year ended December 31, 2015, the Company ... share, as compared to a net loss of $60.5 million, or ...
(Date:2/11/2016)... 11, 2016  Vermillion, Inc. (NASDAQ: VRML ), ... announced the formation of the Steering Committee for its ... --> Pelvic masses can present physicians and ... Once pregnancy is ruled out, pelvic masses may include ... endometriosis, benign ovarian tumors and gastrointestinal and urinary tract ...
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... QGEN ; Frankfurt Prime Standard: QIA) today announced the ... Panels for gene expression profiling, expanding QIAGEN,s portfolio of ... panels enable researchers to select from over 20,000 human ... discover interactions between genes, cellular phenotypes and disease processes. ...
Breaking Biology Technology:
(Date:2/11/2016)... , Feb. 11, 2016  According to new research ... mainstream. More than 200 fingerprint, iris, and eye-vein ... under 70 brand names. This includes market leaders ... ZTE. Acuity projects that 600 million biometric smartphones ... global installed base. Maxine Most , ...
(Date:2/11/2016)... Feb. 11, 2016  Vigilant Solutions announces today that its ... being used by Lee,s Summit Police ... location and arrest of a homicide suspect. ... covers around 65 square miles and is home to roughly ... has a single mobile license plate reader system and also ...
(Date:2/10/2016)... February 10, 2016 ... to 2016 iris recognition market report, combined ... is more widely accepted for border control. ... fingerprint and iris recognition technology in a ... avoid purchasing two individual biometrics devices. ...
Breaking Biology News(10 mins):